

ACNP

AMERICAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY

62nd

ANNUAL MEETING

GENERAL INFORMATION

HYBRID MEETING

**JW Marriott Tampa Water Street/Tampa Marriott Water Street
Tampa, Florida**

DECEMBER 3-6, 2023

Disclosures for 2023 speakers (mini-panels, panel, study group, and plenary) and poster presenters may be found online at: <https://acnp.org/> (click the Annual Meeting tab)

TABLE OF CONTENTS

Acknowledgments	Page 3
ACNP Council	Page 4
Program Committee	Page 4
In Memoriam	Page 5
General Information	Page 6
Dates and Location	Page 6
Annual Meeting Schedule	Page 6
Executive Office Information	Page 6
Code of Conduct	Page 6
Americans with Disabilities Act	Page 7
Program Overview	Page 7
Statement of Need	Page 7
Target Audience	Page 8
Learning Objectives	Page 8
Meeting Evaluation	Page 8
Continuing Medical Education (CME)	Page 8
Disclosures	Page 9-15

Acknowledgements

The American College of Neuropsychopharmacology appreciates the support of our supporting corporations:

AbbVie
ACADIA Pharmaceuticals Inc.
Alkermes, Inc.
Alto Neuroscience
Axsome Therapeutics, Inc.
Biogen Inc.
Boehringer Ingelheim
CenExel Therapeutics
Cerevel Therapeutics, LLC
Clinilabs Drug Development Corporation
COMPASS Pathways
Cybin
Delix Therapeutics
EiSai Inc.
EMA Wellness
Engrail Therapeutics, Inc.
Evolution Research Group
H. Lundbeck A/S
Hoffman-La Roche
Intra-Cellular Therapies, Inc.
IQVIA
Karuna Therapeutics, Inc.
Merck & Co., Inc.
Neumora Therapeutics, Inc.
Neurocrine Biosciences, Inc.
Osmind Inc.
Otsuka Pharmaceutical Development and Commercialization, Inc.
Relmada Therapeutics, Inc.
Sage Therapeutics, Inc.
Signant Health (Bracket Global)
Sunovion Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc.

ACNP Council

Officers and Council

<i>President</i>	Kerry Ressler
<i>President-Elect</i>	Helen Mayberg
<i>President-Elect Designate</i>	William Carlezon
<i>Past President (2022)</i>	Carlos Zarate
<i>Past President (2021)</i>	Linda Brady
<i>Secretary</i>	Rita Valentino
<i>Treasurer</i>	David Rubinow
<i>Diversity & Inclusion Officer</i>	Cynthia Crawford

<i>Council</i>	Carrie Bearden Ellen Leibenluft Lisa Monteggia Marina Picciotto Deanna Barch Colleen McClung
----------------	---

<i>Associate Council Members</i>	Nina Kraguljac Angela Ozburn
----------------------------------	---------------------------------

<i>Council-Elect</i>	C. Neill Epperson Yasmin Hurd
----------------------	----------------------------------

Program Committee

2023 Program and Scientific Communications Committee

<i>Chair</i>	Victoria Risbrough
<i>Co-Chair</i>	Tracy Bale
<i>Council Liaison</i>	Helen Mayberg

Members:

R. Alison Adcock	Carolina Haass-Koffler	Leah Mayo
Tallie Z. Baram	Ebrahim Haroon	Caroline Menard
Staci Bilbo	Markus Heilig	Hirofumi Morishita
Jennifer Blackford	Tiffany Ho	Minae Niwa
Kristen Brennand	Thomas Hyde	George Papkostas
Melissa Brotman	Sheena Josselyn	Martin Paulus
Katherine Burdick	Thomas Kash	Marta Pecina
Christine Anne Denny	Drew Kiraly	Mikhail Pletnikov
Susan Ferguson	Scott Langenecker	Millie Rincón-Cortés
Cecilia Flores	William Lawson	Gerard Sanacora
Erika Forbes	Alex Leow	Yavin Shaham
David Glahn	Israel Liberzon	Rajita Sinha
Steven Grant	Robert Malenka	Keven Spencer
Hanna Stevens	Brian Trainor	
Garret Stuber	Madhukar Trivedi	

In Memoriam

Seymour Fisher
January 11, 2023

Barbara H. Stanley
January 25, 2023

Robert M.A. Hirschfeld
February 10, 2023

Robert I. Taber
June 12, 2023

Sam J. Enna
June 15, 2023

George K. Aghajanian
July 4, 2023

Eugene Paykel
September 3, 2023

John A. Sweeney
September 11, 2023

Roland Griffiths
October 16, 2023

General Information

Dates and Location

Dates: Sunday, December 3, 2023 - Wednesday, December 6, 2023
Location: Hybrid Meeting:
JW Marriott Tampa Water Street/Tampa Marriott Water Street
Virtual Meeting Platform

Future ACNP Annual Meetings

<u>Dates</u>	<u>Hotel</u>	<u>Location</u>
December 8 - 11, 2024	JW Marriott Desert Ridge Resort	Phoenix, Arizona
January 8 - 11, 2026	Atlantis, Bahamas	Paradise Island, Bahamas

Annual Meeting Schedule

All scientific registrants can access the Annual Meeting Schedule for the 62nd ACNP Annual Meeting at: <https://acnp.societyconference.com/conf/#sessions/conf10033>

ACNP Executive Office

ACNP Executive Office
5034A Thoroughbred Lane
Brentwood, Tennessee 37027
USA

Phone: 615-324-2360
Fax: 615-523-1715
E-mail: acnp@acnp.org

Code of Conduct

The American College of Neuropsychopharmacology is dedicated to providing a safe and productive experience for all participants and attendees at all official ACNP events regardless of sex, race, color, national origin, religion, age, physical or mental disability, perceived disability, ancestry, marital status, sexual orientation, gender identity, or any other basis protected by federal or pertinent state laws. ACNP does not tolerate discrimination or any form of prohibited harassment and is committed to enforcing this Code of Conduct (the “Code”) at its Annual Meeting or at any other ACNP event. Please [click here](#) for full Code of Conduct.

Americans with Disabilities Act

It is the policy of the American College of Neuropsychopharmacology not to discriminate against any person on the basis of disabilities. If you feel you need services or auxiliary aids mentioned in this act in order to fully participate in this continuing education activity, please call the Executive Office at 615-324-2360 or send an email to acnp@acnp.org.

Program Overview

Statement of Need

The field of Neuropsychopharmacology is in need of leveraging the wealth of available clinical and preclinical data to improve the quality of research and clinical practice. There are clear unmet needs in effectively treating psychiatric disorders, yet the field has struggled to deliver novel therapeutics (Hyman, 2014; Bernal et al., 2016). There is a need for translating findings from genome-wide association studies for psychiatric disorders into new targets for therapeutics discovery and clinically useful biomarkers of risk (Breen, 2016). There is an acute need for novel precision medicine approaches in psychiatry, including clinical biomarkers to inform diagnosis and prognosis for neurodegenerative diseases and psychiatric disorders (e.g., neuroimaging, electrophysiological and inflammatory markers in blood and/or CSF, and validating clinical prognostic markers of disease risk and treatment response). There are new quantitative biological approaches for understanding and classifying neuropsychiatric disorders (Kas et al., 2017) and emerging digital technologies (mobile, computer, and device-based cognitive tools) providing objective measurements in clinical trials (Krishna, 2017). Best practices in research laboratories and the clinic will benefit from the dissemination of these emerging tools and information in parallel with development of advanced statistical approaches, with the fields of basic and clinical neuroscience providing an enormous amount of novel information and potentially clinically viable metrics. Integrating such information, technology and novel statistical approaches into research and clinical activities is needed to drive the field forward and towards developing more effective treatments. This type of progress is what we need for industry to eventually deliver novel psychiatric medications (O'Donnell and Ehlers, 2015) and breakthrough therapy designations.

REFERENCES

- Bernal A, Steckler T, Altevogt B, Koustova E, Skolnick P, Deaver D, Millan MJ, Bastlund JF, Doller D, Witkin J, Moser P, O'Donnell P, Ebert U, Geyer MA, Prinszen E, Ballard T, Macleod M (2016) Failed trials for central nervous system disorders do not necessarily invalidate preclinical models and drug targets. *Nat Rev Drug Discov* 15:516.
- Breen G, [Li Q](#), [Roth BL](#), [O'Donnell P](#), [Didriksen M](#), [Dolmetsch R](#), [O'Reilly PF](#), [Gaspar HA](#)¹, [Manji H](#), [Huebel C](#), [Kelsoe JR](#), [Malhotra D](#), [Bertolino A](#), [Posthuma D](#), [Sklar P](#), [Kapur S](#), [Sullivan PF](#), [Collier DA](#), [Edenberg HJ](#). Translating genome-wide association findings into new therapeutics for psychiatry. *Nat Neurosci*. 2016 Oct 26;19(11):1392-1396. doi: 10.1038/nn.4411.
- [Kas MJ](#), [Penninx B](#), [Sommer B](#), [Serretti A](#), [Arango C](#), [Marston H](#) ((2017) A quantitative approach to neuropsychiatry: The why and the how. *Neurosci Biobehav Rev*. 2017

Dec 12. pii: S0149-7634(17)30534-1. doi: 10.1016/j.neubiorev.2017.12.008. [Epub ahead of print]

Krishna R (2017) The emerging role of digital technologies in early clinical development. Clin Pharmacology and Therapeutics <https://doi.org/10.1002/cpt.906>

Hyman SE (2014) Revitalizing psychiatric therapeutics. Neuropsychopharmacology 39:220-229.

O'Donnell P, Ehlers MD (2015) Opportunities for New Drug Development in Psychiatry: A Glass Half-Full. JAMA Psychiatry 72:1067-1068.

Target Audience

The target audience includes members of the American College of Neuropsychopharmacology and invited experts. The audience includes physicians, psychologists, and basic neuroscientists from across the globe. The physicians include a number of specialties, with psychiatrists representing the majority of attendees, and neurologists next most common. Psychologists include clinical psychologists and neuropsychologists.

Learning Objectives

After participating in this CME activity, participants should be able to describe and discuss:

1. How the results of recent or ongoing basic science and/or clinical studies of psychiatric disorders in your area of interest or a related area impact your current or potential future research projects.
2. How you will change or modify a current approach or strategy in your current or potential future research projects based on what you learned from the results of recent or ongoing basic science and/or clinical studies of psychiatric disorders in your area of interest or a related area.
3. How recent progress in identifying genetic variations that are risk factors for the development of psychiatric disorders affect your current or potential future research projects.

Meeting Evaluation

All meeting attendees are urged to complete an evaluation of the meeting. Attendees who are requesting CME credit for the meeting are required to complete the evaluation. This form is available online only. You may complete the evaluation on-line at <https://acnp.org/> (click the Annual Meeting tab). All evaluations must be completed by **January 12, 2024**.

Continuing Medical Education and Disclosures

Attendees will be eligible to receive the credit hours listed below for attending the full 62nd Annual Meeting, December 3 - 6, 2023. The credit hour totals below include attending all available session times Sunday, December 3 - Wednesday, December 6, 2023. To obtain CME credits for the conference, you must complete the post-conference meeting evaluation.

There will be a \$40.00 charge for scientific registrants to obtain CME credits. CME instructions will be available on the ACNP website (<https://acnp.org/>). Upon completion of the post-conference evaluation and attestation, your CME certificate will be emailed automatically.

Satisfactory Completion

Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.



JOINTLY ACCREDITED PROVIDER™

INTERPROFESSIONAL CONTINUING EDUCATION

Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Amedco Joint Accreditation #4008163.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and American College of Neuropsychopharmacology (ACNP). Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians (ACCME) Credit Designation

Amedco LLC designates this **live activity** for a maximum of **25.50 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Amedco LLC designates this **enduring material** for a maximum of **101.75 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

****You should not claim both live and enduring hours for the same content.***

Disclosure of Relevant Financial Relationships with Commercial Interests

In order to meet ACCME requirements, Amedco requires [disclosure](#) of financial relationships from individuals in a position to control the content of a CME activity; to identify and resolve conflicts of interest related to those relationships; and to make disclosure information available to the audience prior to the CME activity. Presenters are required to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentations. A copy of the disclosures can be found on the mobile app and online at <https://acnp.org/>.

ACCME requires that all individuals in control of the educational content must disclose all financial relationships within the past 12 months with all commercial interest entities, even if it is disclosing they have nothing to disclose. All conflicts of interest will be resolved prior to the educational activity being delivered. An individual who refuses to disclose relevant financial relationships cannot have control of, or responsibility for, the development, management, presentation or evaluation of the CME activity.

Financial Relationships

Definition of Financial Relationship...

Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria for promotional speakers' bureau, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. ACCME considered relationships of the person involved in the CME activity to include financial relationships of a spouse or partner. Contracted research includes research funding where the institution gets the grant and manages the fund and the person is the principal or named investigator on the grant. There is no minimum dollar amount for relationships.

Definition of Commercial Interest...

A *commercial interest* is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Providers of clinical service directly to patients are not commercial interests – unless the provider of clinical service is owned, or controlled, by a commercial interest. The following are not commercial interests:

- 501-C Non-profit organizations that do not advocate for commercial interests
- Government organizations
- Non-health care related companies
- Liability insurance providers
- Health insurance providers
- Group medical practices
- For-profit hospitals
- For-profit rehabilitation centers
- For-profit nursing homes
- Blood banks
- Diagnostic laboratories

Relevant financial relationships exist between the following individuals and commercial interests:

2023 Council Disclosures

Carlezon, William: Self: ANCP (Honoraria), Self: Psy Therapeutics (Consultant), Self: Cerevel Therapeutics (Contracted Research), Self: Alto Neuroscience (Contracted Research), Spouse: Biogen (Employee)

Mayberg, Helen: Self: Abbott Labs (Consultant), Self: Abbott Labs (Patent), Self: Cogwear (Advisory Board), Self: Blackrock Neuro (Advisory Board)

McClung, Colleen: Self: Alkermes (Advisory Board)

Ressler, Kerry: Self: Sage Therapeutics (Advisory Board), Self: Boehringer Ingelheim (Advisory Board), Self: Senseye, Inc (Advisory Board), Self: Bioxccl (Consultant), Self: Bionomics (Consultant), Self: Jazz Pharma (Consultant), Self: Acer Therapeutics (Consultant),

Self: Alto Neuroscience (Contracted Research), Self: Brain Research Foundation (Advisory Board), Self: Brain and Behavior Research Foundation (Advisory Board)

Rubinow, David: Self: Sage Therapeutics (Advisory Board), Self: Sensorium Therapeutics (Advisory Board), Self: EmbarkNeuro (Advisory Board), Self: Baszucki Foundation (Grant), Self: Bria Bioscience (Consultant), Self: Aldeyra Therapeutics (Consultant), Self: GH Research (Consultant)

Zarate, Carlos: Self: Ketamine and metabolites (Patent)

Council Members with No Disclosures

Barch, Deanna
Bearden, Carrie
Brady, Linda
Crawford, Cynthia
Leibenluft, Ellen
Nina Kraguljac
Angela Ozburn
Picciotto, Marina
Valentino, Rita

2023 Program Committee Disclosures

Adcock, Alison R.:

Editas: Stock/Equity (Self)

Bale, Tracy:

Ambit Therapeutics, Terran Biologicals: Royalties (Spouse).

Brennan, Kristen:

Arvinas: Employee (Spouse). Neuro Pharmaka: Consultant (Self). Rumi Scientific: Advisory Board (Self)

Burdick, Katherine:

Breakthrough Discovering for thriving with Bipolar Disorder: Grant (Self), Advisory Board (Self), Honoraria (Self).

Denny, Christine Ann:

Lenox Hill Radiology (Radiologist): Employee (Spouse). CUIMC: Patents (Self), Employee (Self). RFMH, NYPSI: Employee (Self).

Heilig, Markus:

Indivior: Advisory Board (Self), Contracted Research (Self). CAMURUS, Molteni, Aelis, Brainsway, Lundbeck, Pfizer: Advisory Board (Self). Janssen: Grant (Self).

Langenecker, Scott:

Secondary Triad, Inc.: Board Member (Self).

Leow, Alex:

KeyWise AI: Founder (Self).

Malenka, Robert:

MapLight Therapeutic: Founder (Self). Mindmed, Bright Minds, Aelis Farma: Advisory Board (Self).

Papakostas, George:

JNJ, Beckley: Contracted Research (Self). Otsuka, Lundbeck: Honoraria (Self). Boehringer Ingelheim: Consultant, Honoraria (Self). Praxis, Merck, Neurocentria, Sertsei, Almatica: Consultant (Self).

Paulus, Martin:

UpToDate: Honoraria (Self). Spring Health: Board Member (Self). Roche Pharmaceuticals: Consultant (Self). Engrail Therapeutics: Employee (Spouse)

Risbrough, Victoria:

Jazz Pharmaceuticals, Engrail: Advisory Board (Self)

Sanacora, Gerard:

Abbvie, Aptinyx, Atai, Axsome, Biogen, Bristol-Myers Squibb, Clexio, Cowen, Donovo Biopharma, Daiichi Sankyo, ECR1, EMA Wellness, Gilgamesh, Janssen, KOA Health, Levo Therapeutics, Merck, MiCure, Navitor Pharmaceuticals, Neurocrine, Novartis, Noven Pharmaceuticals, Praxis Therapeutics, Sage Pharmaceuticals, Seelos Pharmaceuticals, Taisho Pharmaceuticals, Valeant, XW Labs: Consultant (Self). Ancora/Embark: Advisory Board (Self). Biohaven Pharmaceuticals: Founder, Stock/Equity (Self). Freedom Biosciences, Relmada Therapeutics: Stock/Equity (Self). Janssen, Merck, Usona Institute: Contracted Research (Self). Perception Neuroscience, Relmada Therapeutics, Tetricus, Vistagen Therapeutics: Advisory Board (Self).

Sinha, Rajita:

CT Pharma: Grant (Self). Embera Neurotherapeutics, Menda Health: Advisory Board (Self). Aelis Farma: Contracted Research (Self). Aptinyx Inc: Other Financial or Material Support (Self).

Spencer, Kevin:

Pacific Development and Technology: Consultant (Self).

Trivedi, Madhukar:

NIMH, NIDA, American Foundation for Suicide Prevention, Patient-Centered Outcomes Research Institute, Blue Cross Blue Shield of Texas: Contracted Research (Self). Acadia Pharmaceuticals, Alkermes Inc., Axsome Therapeutics, Biogen MA Inc., Cerebral Inc., Circular Genomics Inc., Compass Pathfinder Limited, GH

Research Limited, Janssen, Legion Health Inc., Merck Sharp & Dohme Corp., MindMed Inc., Myriad Neuroscience, Naki Health, Ltd., Neurocine Biosciences Inc., Noema Pharma AG, Orexo US Inc., Otsuka, Praxis Precision Medicines, Inc., Relmada Therapeutics, Inc., SAGE Therapeutics, Sparian Biosciences, Titan Pharmaceuticals Inc., WebMD: Consultant (Self). Alto Neuroscience, GreenLight VitalSign6, Heading Health, Signant Health: Advisory Board (Self)

The following committee members had nothing to disclose:

Baram, Tallie Z.
Bilbo, Staci
Blackford, Jennifer
Brotman, Melissa
Ferguson, Susan
Flores, Cecilia
Forbes, Erika
Glahn, David
Grant, Steven
Haass-Koffler, Carolina
Haroon, Ebrahim
Hyde, Thomas
Josselyn, Sheena
Kash, Thomas
Kiraly, Drew

Lawson, William
Liberzon, Israel
Mayo, Leah
Menard, Caroline
Morishita, Hirofumi
Niwa, Minae
Pecina, Marta
Pletnikov, Mikhail
Rincón-Cortés, Millie
Risbrough, Victoria
Shaham, Yavin
Stevens, Hanna
Stuber, Garret
Trainor, Brian

2023 Staff Members Disclosures

Kunath, Lori:

Spouse: Quorum Healthcare (Employee)

Staff members with nothing to disclose:

Jill Bracey
Ciana Centurion
Evan Dickert
Kelly Phy
Liz Sansom

Rebecca Shannon
Erin Shaw
Tori Swinehart
Sarah Timm